In 2025, EudraVigilance received more than 1.69 million individual case safety reports from companies and clinical trial sponsors. As safety data moves across countries, consistent standards become essential for accurate reporting and regulatory oversight. Therefore, Harmonization in pharmacovigilance helps align reporting formats, terminology, and safety processes across regulatory systems. However, pharmaceutical companies must still manage regional requirements carefully to maintain compliance and inspection readiness.
Inhaltsverzeichnis
What Is Harmonization in Pharmacovigilance?
Harmonization in pharmacovigilance creates common principles for collecting, evaluating, and reporting medicine safety data across markets. It supports consistent terminology, data structures, ICSR reporting, and benefit risk assessment. However, harmonization does not make national pharmacovigilance regulations identical. Therefore, companies still need strong global procedures that align international standards with local reporting duties, regulatory timelines, and authority expectations.
Why Consistent Safety Reporting Matters for Regulatory Compliance?
Consistent safety reporting helps pharmaceutical companies maintain accurate, timely, and traceable safety data across markets. It also supports reliable reconciliation between safety databases, affiliates, partners, and regulatory submissions. Therefore, harmonized global safety reporting reduces gaps that may lead to late cases, inconsistent records, or weak inspection evidence. During a pharmacovigilance inspection, regulators expect companies to show that reported safety information remains complete, controlled, and consistent throughout the reporting process.
The infographic shows how a safety case moves from initial receipt through ICSR processing and regulatory reporting to become traceable evidence for compliance and inspection readiness.
4 Regulatory Systems That Make Global Alignment Possible
Global pharmacovigilance depends on shared regulatory frameworks that help companies manage safety data consistently across markets. These frameworks standardize how teams exchange ICSRs, review cumulative safety evidence, assess signals, and prepare for inspection. However, each system addresses a different part of the safety lifecycle, so companies must understand how they work together.
The four areas below show how international standards turn pharmacovigilance harmonization into practical regulatory control:
- Standardizing ICSR Data Exchange with ICH E2B R3 (Available PDF)
- Harmonizing Periodic Benefit Risk Reporting with ICH E2C R2 (Available PDF)
- Aligning Signal Management Across Regulatory Systems (Available PDF)
- Harmonization Through Risk Based Pharmacovigilance Inspections (Available PDF)
Standardizing ICSR Data Exchange with ICH E2B R3 (Available PDF)
ICH E2B R3 standardizes the structure and electronic exchange of individual case safety reports between companies and regulators. It improves consistency, interoperability, and traceability of global safety data.
Harmonizing Periodic Benefit Risk Reporting with ICH E2C R2 (Available PDF)
ICH E2C R2 provides a common format for periodic benefit risk evaluation throughout a product’s lifecycle. It helps organizations assess cumulative safety data consistently across markets.
Download Periodic Benefit-Risk Evaluation Report (PBRER) E2C(R2) Here
Aligning Signal Management Across Regulatory Systems (Available PDF)
Harmonized signal management creates a structured process for detecting, validating, prioritizing, assessing, and acting on safety signals. It supports consistent regulatory decisions and timely risk management.
Harmonization Through Risk Based Pharmacovigilance Inspections (Available PDF)
Risk-based pharmacovigilance inspections focus oversight on systems and activities with the highest compliance or patient safety risk. A consistent inspection approach helps regulators assess whether global pharmacovigilance controls work effectively in practice.
Where Global Pharmacovigilance Requirements Still Differ?
International harmonization gives pharmaceutical companies common standards for safety terminology, data exchange, and case assessment. However, pharmacovigilance regulations still differ across major markets. Therefore, global teams must control local reporting timelines, submission routes, case categories, and authority expectations. These differences make a clear regulatory requirements matrix essential for accurate ICSR reporting and inspection readiness.
The table below compares key post-marketing safety reporting requirements across major regulatory regions and shows where local implementation still differs.
| Region | Expedited Reporting | Other ICSR Reporting | Main Regulatory Route | Key Difference |
|---|---|---|---|---|
|
European Union |
Serious valid ICSRs: within 15 days |
Non-serious valid ICSRs: within 90 days |
EudraVigilance |
EU rules use harmonized ICH standards, but reporting scope and local regulatory obligations still require control. |
|
United Kingdom |
Serious UK and qualifying non-UK ICSRs: within 15 days |
Non-serious UK ICSRs: within 90 days |
MHRA ICSR Submissions or Gateway |
UK requirements apply nationally, while Northern Ireland can also trigger specific EudraVigilance obligations. |
|
United States |
Serious and unexpected post-marketing adverse experiences: within 15 calendar days |
Other adverse experiences generally enter periodic reporting requirements |
FDA FAERS |
FDA focuses expedited reporting on serious and unexpected cases rather than applying a general 90-day rule to non-serious ICSRs. |
|
Japan |
Certain reportable adverse reactions require submission within 15 days |
Other specified adverse reactions may require reporting within 30 days |
PMDA through the Japanese MAH |
Japan uses report categories and regulatory criteria that differ from the EU 15-day and 90-day model. |
How to Build a Harmonized Global Pharmacovigilance System
A harmonized global pharmacovigilance system turns international standards into consistent daily practice. Companies need controlled SOPs, clear safety database rules, local procedures, reconciliation processes, training, governance, and compliance monitoring. Therefore, strong global pharmacovigilance depends on both standardization and effective local implementation. This approach also helps teams improve ICSR reporting, maintain data quality, and prepare stronger evidence for inspection.
The infographic shows eight core controls that connect global standards with local pharmacovigilance operations and inspection-ready evidence
Final Words
In 2025, more than 90% of EU and EEA pharmacovigilance inspections were conducted through national inspection programmes. This shows why global standards alone cannot guarantee consistent compliance across markets. Therefore, Harmonization in pharmacovigilance must connect international requirements with effective local procedures, clear responsibilities, and reliable inspection evidence. Companies that maintain this alignment are better prepared to demonstrate control across their global safety systems.
Quality Management System
We work with pharmaceutical teams to design, implement, and run effective Quality Management Systems, covering change control, CAPA, deviations, and audits to support consistent GMP compliance.
FAQ
Inspectors typically expect consistent SOPs, case-processing rules, MedDRA coding, reporting timelines, reconciliation records, training evidence, and traceable safety database records across markets.
Companies should maintain a controlled global framework, document local regulatory differences, assign clear responsibilities, and update procedures whenever national requirements change.
Common risks include late ICSR reporting, inconsistent MedDRA coding, weak reconciliation, unclear affiliate responsibilities, incomplete training records, and poor control of local reporting requirements.
References
Marco Klinger is Head of Quality Services at Zamann Pharma Support, where he leads consulting teams through complex regulatory and quality-driven projects. He brings more than 15 years of hands-on compliance experience across regulated industries. His work includes close collaboration with companies such as Reckitt, Sanofi, Biotech, Biotest, and others. Marco has deep expertise in medical device development, aseptic manufacturing, and the design, implementation, and management of complete quality management systems within GMP-regulated environments.